C-Reactive Protein, Interleukin-6, and Vascular Recurrence According to Stroke Subtype
John McCabe, Cathal Walsh, Sarah Gorey, Katie Harris, Pablo Hervella, Ramón Iglesias‐Rey, Christina Jern, Linxin Li, Nobukazu Miyamoto, Joan Montaner, Annie Pedersén, Francisco Purroy, Peter M. Rothwell, Cathie Sudlow, Yuji Ueno, Mikel Vicente‐Pascual, William Whiteley, Mark Woodward, Peter J. Kelly
Abstract
BACKGROUND AND OBJECTIVES: Anti-inflammatory therapies reduce major adverse cardiovascular events (MACE) in coronary artery disease but remain unproven after stroke. Establishing the subtype-specific association between inflammatory markers and recurrence risk is essential for optimal selection of patients in randomized trials (RCTs) of anti-inflammatory therapies for secondary stroke prevention. METHODS: transformation. We then did study-level meta-analysis with comparable published studies not providing IPD. Preferred Reporting Items for Systematic Review and Meta-Analyses IPD guidelines were followed. RESULTS: = 0.03). Findings were consistent on study-level meta-analysis of the IPD results with 2 other comparable studies (20,136 patients). DISCUSSION: Our data provide new evidence for the selection of patients in future RCTs of anti-inflammatory therapy in stroke due to large artery atherosclerosis, small vessel occlusion, and undetermined etiology according to inflammatory marker profile.